drug
emugrobart
Phase 2updated 6mo agoby F. Hoffmann-La Roche Ltd
Phase 2community read0 votes
indications
indications
Obesity
all catalysts(0)
nothing on the calendar yet
News(8)
- Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T assetAside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.biospace · 25d ago
- Roche expands obesity R&D footprint with Rona deal worth $1B+Roche has gained access to a genetic obesity approach from China's Rona Therapeutics for up to $100 million in upfront and near-term payments.biospace · 1mo ago
- Roche cuts muscle-sparing obesity drug after mid-stage disappointmentRoche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary…biospace · 1mo ago
- STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and moreNovo has agreed to pay up to $2.6 billion to license an experimental, weekly weight loss pill from China’s Hengrui Pharmastat · 1mo ago
- Roche cans muscle-preserving obesity drug, hands it back to ChugaiRoche has scrapped development of a muscle-building drug, ending a trial testing the experimental medicine in combination with an anti-obesity injectable. The Swiss pharma is stopping work on emugr…endpoints · 1mo ago
- Roche drops muscle-sparing obesity antibody after flunked interim analysisRoche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study.fiercebiotech · 1mo ago
- Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerateCurrent leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 bil…biospace · 2mo ago
- Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanismRoche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage urocortin-2 analog from South Korea’s Hanmi Pharm.fiercebiotech · 2mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that